Drug
Dordaviprone
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Other Targeted Agents |
| Group | ClpP protease activator |
| Mechanism of Action | ClpP protease activator |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing (mitochondrial ClpP hyperactivation → OXPHOS collapse, ISR, TRAIL/DR5 death; RER >1) (Zhou et al., Oncotarget, 2025; Amoroso et al., Scientific Reports, 2021). Sensitization appears tumor-biased in preclinical models; theoretical normal-tissue adverse events is undefined.
Data on this page refer exclusively to patients treated with
Dordaviprone combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
ClpP protease activator group page.